KENILWORTH, NJ — June 28, 2002 —
Schering-Plough Corporation announced today that Clarinex 5 mg Reditabs, a rapidly disintegrating tablet formulation of the nonsedating antihistamine desloratadine, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of allergy symptoms caused by perennial indoor and seasonal outdoor allergens and chronic idiopathic urticaria (CIU), or hives of unknown cause, in adults and children 12 years of age and older.
Clarinex Reditabs follows Clarinex 5 mg Tablets as the second formulation of Clarinex to be
approved by the FDA. The company plans to launch the product pending FDA approval of a quality control test revision, the supplement for which has already been submitted, and the build-up of sufficient inventories. Scherer DDS Ltd. manufactures Clarinex Reditabs for Schering-Plough.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!